专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明授权

US06169194A High surface density covalent immobilization of oligonucleotide monolayers using a 1-(thiotrifluoroacetato)-11-(trichlorososilyl)-undecane linker 失效
标题翻译：使用1-（三（三氟乙酰））-11-（三氯硅烷基） - 十一烷接头的高密度共价固定寡核苷酸单层
公开(公告)号：US06169194A
公开(公告)日：2001-01-02
申请号：US08951448
申请日：1997-10-16
申请人： Michael Thompson , Mark E. McGovern
发明人： Michael Thompson , Mark E. McGovern
IPC分类号： C07F712
CPC分类号： B82Y30/00 , B01J20/3242 , B32B17/10688 , B82Y5/00 , B82Y15/00 , C03C17/30 , C03C17/3405 , C07B2200/11 , C07H21/00 , Y10S977/702 , Y10S977/902 , Y10S977/92 , Y10S977/924 , Y10S977/958
摘要： Oligonucleotides and other biomolecules are immobilized in high density on solid substrates through covalent forces using either a permanent thioether bond, or a chemoselectively reversible disulfide bond to a surface thiol. Substrates which have hydroxyl groups on their surfaces can be first silanized with a trichlorosilane containing 2-20 carbon atoms in its hydrocarbon backbone, terminating in a protected thiol group. The oligonucleotides or other biomolecules are first connected to a tether consisting of a hydrocarbon or polyether chain of 2-20 units in length which terminates in a thiol group. This thiol may be further modified with a halobenzylic-bifunctional water soluble reagent which allows the conjugate to be immobilized onto the surface thiol group by a permanent thioether bond. Alternatively, the oligonucleotide-tether-thiol group can be converted to a pyridyldisulfide functionality which attaches to the surface thiol by a chemoselectively reversible disulfide bond. The permanently bound oligonucleotides are immobilized in high density compared to other types of thiol functionalized silane surfaces and to the avidin-biotin method.
摘要翻译：寡核苷酸和其他生物分子通过共价力使用永久硫醚键或与表面硫醇的化学选择性可逆二硫键以高密度固定在固体基质上。在其表面上具有羟基的底物可以首先在其烃骨架中用含有2-20个碳原子的三氯硅烷硅烷化，终止于受保护的硫醇基团。寡核苷酸或其他生物分子首先连接到由长度为2-20单位的烃或聚醚链组成的系链，其终止于硫醇基团。该硫醇可以用卤代苄基双功能水溶性试剂进一步改性，其允许缀合物通过永久硫醚键固定在表面硫醇基上。或者，寡核苷酸 - 系链 - 硫醇基团可以转化成通过化学选择性可逆的二硫键附着于表面硫醇的吡啶基二硫键官能团。与其他类型的硫醇官能化硅烷表面和抗生物素蛋白 - 生物素方法相比，永久结合的寡核苷酸以高密度固定。

42. 发明授权

US6106913A Fibrous structures containing nanofibrils and other textile fibers 失效
标题翻译：含纤维结构的纳米纤维和其他纺织纤维
公开(公告)号：US6106913A
公开(公告)日：2000-08-22
申请号：US169116
申请日：1998-10-08
申请人： Frank L. Scardino , Richard J. Balonis
发明人： Frank L. Scardino , Richard J. Balonis
IPC分类号： A61F2/00 , A61F2/02 , A61F2/06 , A61F2/08 , A61F2/28 , A61F2/30 , A61F2/46 , A61L27/12 , D01H4/02 , D02G3/38 , D02G3/44 , B32B1/08
CPC分类号： D01D5/0084 , A61F2/28 , A61F2/30965 , A61L27/12 , D01D5/0076 , D01H4/02 , D02G3/36 , D02G3/448 , A61F2/06 , A61F2/08 , A61F2/30756 , A61F2/3094 , A61F2002/2835 , A61F2002/30062 , A61F2002/30199 , A61F2002/3084 , A61F2002/30914 , A61F2002/30968 , A61F2002/4648 , A61F2210/0004 , A61F2230/0063 , A61F2310/00293 , Y10S977/855 , Y10S977/876 , Y10S977/92 , Y10S977/961 , Y10T428/1369 , Y10T428/2936
摘要： Nanofibers are produced having a diameter ranging from about 4 .ANG. to 1 nm, and a nano denier of about 10.sup.-9. The use of the electro-spinning process permits production of the desired nanofibrils. These fibrils in combination with a carrier or strengthening fibers/filaments can be converted directly into nonwoven fibrous assemblies or converted into linear assemblies(yarns) before weaving, braiding or knitting into 2-dimensional and 3-dimensional fabrics. The electrospun fiber can be fed in an air vortex spinning apparatus developed to form a linear fibrous assembly. The process makes use of an air stream in a properly confined cavity. The vortex of air provides a gentle means to convert a mixture of the fibril fed directly or indirectly from the ESP unit and a fiber mass or filament into an integral assembly with proper level of orientation. Incorporation of thus produced woven products into tissue engineering is part of the present invention.
摘要翻译：生产直径范围为约4至1nm的纳米纤维和约10-9纳米旦尼尔。使用电纺工艺可以生产所需的纳米原纤维。这些原纤维与载体或强化纤维/长丝组合可以直接转化成非织造纤维组件，或者在编织，编织或编织成二维和三维织物之前转化成线性组件（纱线）。电纺纤维可以在开发成形成线性纤维集合体的空气涡旋纺丝装置中进料。该过程使用适当限定的空腔中的气流。空气涡流提供了将来自ESP单元和纤维质量或细丝的直接或间接进料的原纤的混合物转化为具有适当水平取向的整体组件的温和装置。将如此生产的织造产品并入组织工程中是本发明的一部分。

43. 发明授权

US6080423A Three dimensional colorimetric assay assemblies 失效
标题翻译：三维比色测定组件
公开(公告)号：US6080423A
公开(公告)日：2000-06-27
申请号：US944257
申请日：1997-10-06
申请人： Deborah Charych , Anke Reichart
发明人： Deborah Charych , Anke Reichart
IPC分类号： G01N33/543 , G01N33/58 , A61K9/127 , A61J3/00 , G01N21/00
CPC分类号： B82Y5/00 , G01N33/5432 , G01N33/586 , G01N2333/11 , G01N2333/924 , Y10S424/812 , Y10S436/805 , Y10S436/829 , Y10S977/80 , Y10S977/801 , Y10S977/897 , Y10S977/898 , Y10S977/907 , Y10S977/92 , Y10S977/927
摘要： A direct assay is described using novel three-dimensional polymeric assemblies which change from a blue to red color when exposed to an analyte, in one case a flu virus. The assemblies are typically in the form of liposomes which can be maintained in a suspension, and show great intensity in their color changes. Their method of production is also described.
摘要翻译：使用新颖的三维聚合物组合物描述直接测定法，其在暴露于分析物时，从蓝色变为红色，在一种情况下，其为流感病毒。组合物通常为脂质体的形式，其可以保持在悬浮液中，并且在其颜色变化中显示出很大的强度。还描述了他们的生产方法。

44. 发明授权

US6074865A Recombinant dengue virus DNA fragment 失效
标题翻译：重组登革热病毒DNA片段
公开(公告)号：US6074865A
公开(公告)日：2000-06-13
申请号：US504878
申请日：1995-07-20
申请人： Eileen P. Kelly , Alan D. King
发明人： Eileen P. Kelly , Alan D. King
IPC分类号： A61K39/00 , C07K14/18 , C07H21/04 , C12N15/85 , C12N7/00 , C12N15/00
CPC分类号： C07K14/005 , A61K39/00 , C12N2710/14143 , C12N2770/24122 , Y10S977/802 , Y10S977/804 , Y10S977/806 , Y10S977/92
摘要： A recombinant protein encompassing the complete envelope glycoprotein and a portion of the carboxy-terminus of the membrane/premembrane protein of dengue 2 virus was expressed in baculovirus as a protein particle. The recombinant protein particle was purified and found to provide protection against lethal challenge with dengue 2 virus in mice.
摘要翻译：作为蛋白质颗粒，在杆状病毒中表达包含完整包膜糖蛋白和登革热2病毒膜/膜前蛋白的羧基末端部分的重组蛋白。纯化重组蛋白质颗粒，发现在小鼠中提供针对登革热2病毒的致死性攻击的保护。

45. 发明授权

US6025337A Solid microparticles for gene delivery 失效
标题翻译：用于基因递送的固体微粒
公开(公告)号：US6025337A
公开(公告)日：2000-02-15
申请号：US657913
申请日：1996-06-07
申请人： Vu L. Truong , Thomas August , Kam W. Leong
发明人： Vu L. Truong , Thomas August , Kam W. Leong
IPC分类号： A61K9/50 , A61K9/16 , A61K47/48 , A61K48/00 , C12N15/87 , C12N15/88 , C12N15/00 , A01N43/04
CPC分类号： B82Y5/00 , A61K47/48876 , A61K9/167 , C12N15/87 , C12N15/88 , A61K48/00 , Y10S977/906 , Y10S977/907 , Y10S977/916 , Y10S977/92
摘要： A target-specific gene delivery system is made of enzymatically degradable gelatin and nucleic acids (DNA or RNA) microparticles with a linking moiety or a targeting ligand attached to the surface. The delivery system can be made by a simple method. Targeting ligands can be attached to the microparticle directly or via a linking moiety. The linkage design allows the attachment of any molecule onto the microparticle surface including antibodies, cell adhesion molecules, hormones and other cell-specific ligands.
摘要翻译：目标特异性基因递送系统由可酶降解的明胶和具有连接部分的连接部分或连接于表面的靶向配体的核酸（DNA或RNA）微粒制成。输送系统可以通过简单的方法进行。靶向配体可以直接或通过连接部分连接到微粒上。连接设计允许将任何分子附着在微粒表面上，包括抗体，细胞粘附分子，激素和其他细胞特异性配体。

46. 发明授权

US6015686A Eukaryotic layered vector initiation systems 失效
公开(公告)号：US6015686A
公开(公告)日：2000-01-18
申请号：US404796
申请日：1995-03-15
申请人： Thomas W. Dubensky, Jr. , John M. Polo , Douglas J. Jolly , David A. Driver
发明人： Thomas W. Dubensky, Jr. , John M. Polo , Douglas J. Jolly , David A. Driver
IPC分类号： A61K38/00 , A61K48/00 , C07K14/02 , C07K14/045 , C07K14/075 , C07K14/155 , C07K14/16 , C07K14/47 , C07K14/705 , C07K14/755 , C07K14/82 , C12N5/16 , C12N9/24 , C12N15/00 , C12N15/113 , C12N15/33 , C12N15/63 , C12N15/86 , C12N15/861 , C12P21/02 , C12N15/11
CPC分类号： C12N15/113 , C07K14/005 , C07K14/47 , C07K14/705 , C07K14/755 , C07K14/82 , C12N15/1131 , C12N15/86 , C12N9/2402 , C12Y302/01045 , A61K2039/5256 , A61K38/00 , A61K48/00 , C12N2310/111 , C12N2310/122 , C12N2710/10322 , C12N2710/16722 , C12N2730/10122 , C12N2740/15022 , C12N2740/16222 , C12N2770/36122 , C12N2830/002 , C12N2830/42 , C12N2830/60 , C12N2840/20 , C12N2840/203 , C12N2840/206 , C12N2840/44 , C12N2840/85 , Y10S977/773 , Y10S977/804 , Y10S977/808 , Y10S977/918 , Y10S977/92 , Y10S977/924
摘要： The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

47. 发明授权

US6013262A Recombinant papilloma virus L1 失效
标题翻译：重组乳头状瘤病毒L1
公开(公告)号：US6013262A
公开(公告)日：2000-01-11
申请号：US737336
申请日：1997-01-16
申请人： Ian Frazer , Jian Zhou
发明人： Ian Frazer , Jian Zhou
IPC分类号： G01N33/574 , A61K39/00 , A61K39/12 , A61P31/12 , C07K14/025 , C07K16/08 , C12N15/09 , C12N15/34 , C12N15/37 , C12P21/02 , C12R1/19 , C12Q1/70
CPC分类号： C07K14/005 , C07K16/084 , A61K39/00 , C07K2319/00 , C12N2710/20022 , C12N2710/20023 , Y10S977/917 , Y10S977/918 , Y10S977/92
摘要： This invention relates to a recombinant papilloma virus L1 protein which can elicit an immune response which recognises papilloma virus VLP including L1 protein and can form extracellularly a multimeric structure or VLP wherein the multimeric structure comprises a plurality of recombinant papilloma virus L1 proteins. This invention also includes the use of the recombinant papilloma virus L1 protein to detect the presence of papilloma virus and can form the basis of a vaccine for prophylactic and therapeutic use.
摘要翻译： PCT No.PCT / AU95 / 00292 Sec。 371日期1997年1月16日 102（e）日期1997年1月16日PCT提交1995年5月17日PCT公布。出版物WO95 / 31476 日期1995年11月23日本发明涉及可引发免疫应答的重组乳头状瘤病毒L1蛋白，其识别包括L1蛋白的乳头瘤病毒VLP并且可以在细胞外形成多聚体结构或VLP，其中所述多聚体结构包含多个重组乳头状瘤病毒L1 蛋白质。本发明还包括使用重组乳头瘤病毒L1蛋白来检测乳头状瘤病毒的存在并且可以形成用于预防和治疗用途的疫苗的基础。

48. 发明授权

US5989835A System for cell-based screening 失效
公开(公告)号：US5989835A
公开(公告)日：1999-11-23
申请号：US810983
申请日：1997-02-27
申请人： R. Terry Dunlay , D. Lansing Taylor
发明人： R. Terry Dunlay , D. Lansing Taylor
IPC分类号： B01L3/00 , C12Q1/68 , C40B60/14 , G01N15/14 , G01N33/50 , G01N33/58 , G01N33/533
CPC分类号： B82Y30/00 , C12Q1/68 , C12Q1/6813 , G01N15/1475 , G01N21/6428 , G01N21/6452 , G01N21/6458 , G01N33/5005 , G01N33/5035 , G01N33/582 , B01J2219/00315 , B01J2219/00317 , B01J2219/00707 , B01J2219/00743 , B01L3/5085 , C40B60/14 , G01N2015/1486 , G01N2015/1497 , G01N2021/6419 , G01N2021/6482 , Y10S436/80 , Y10S436/807 , Y10S436/809 , Y10S977/795 , Y10S977/881 , Y10S977/92 , Y10S977/941 , Y10S977/942
摘要： The invention relates to an optical system for determining the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for specific biological activity. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a fluorescent microscope, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropaterned array of locations. The invention includes apparatus and computerized method for processing, displaying and storing the data.

49. 发明授权

US5981254A Process for producing thrombin from plasma 失效
标题翻译：从血浆中生产凝血酶的方法
公开(公告)号：US5981254A
公开(公告)日：1999-11-09
申请号：US960660
申请日：1997-10-30
申请人： Trung Bui-Khac
发明人： Trung Bui-Khac
IPC分类号： C12N9/74 , A61K35/14 , A61K38/00 , A61K38/45 , A61K38/46 , A61K38/48 , A61L2/00 , A61L24/00 , A61L24/10 , C07K1/14 , C07K14/745 , C07K14/75 , C07K14/78
CPC分类号： C07K14/745 , A61K38/45 , A61L2/0017 , A61L24/106 , Y10S977/904 , Y10S977/906 , Y10S977/908 , Y10S977/92
摘要： This invention relates to a process for preparing biological glue components from a plasma pool which combines high recovery, quality product and viral safety. In first instance, a triple viral inactivated product comprising fibrogen, fibronectin and FXIII is obtained by treating a concentrate thereof first with a viricide solvent/detergent solution, second with viral nanofiltration, and third with heat. The recovery of a good quality product is not compromised by the process of the invention. In second instance, the same steps are reproduced for obtaining a triple viral safe thrombin product. In that case, a known proprietary process has been improved to increase the recovery of active thrombin by about two fold. One of the steps which increase the yield of thrombin is the dilution of the prothrombin solution with water 4 volumes to 1 volume prothrombin prior to acid precipitation.
摘要翻译：本发明涉及一种从血浆池制备生物胶组分的方法，其结合了高回收率，优质产品和病毒安全性。首先，通过首先用杀病毒剂溶剂/洗涤剂溶液处理浓缩物，然后用病毒纳滤过滤，然后加热加热，获得包含纤维素，纤连蛋白和FXIII的三重病毒灭活产物。本发明的方法不会损害高质量产品的回收。在第二种情况下，为了获得三重病毒安全性凝血酶产物，再现相同的步骤。在这种情况下，已经改进了已知的专利方法，以将活性凝血酶的回收率增加约2倍。提高凝血酶产量的步骤之一是在酸沉淀之前用水4体积至1体积的凝血酶原将凝血酶原溶液稀释。

50. 发明授权

US5928647A Inducing cytotoxic T lymphocyte responses 失效
标题翻译：诱导细胞毒性T淋巴细胞反应
公开(公告)号：US5928647A
公开(公告)日：1999-07-27
申请号：US481327
申请日：1995-09-15
申请人： Kenneth Rock
发明人： Kenneth Rock
IPC分类号： A61K47/48 , A61K9/16 , A61K9/18 , A61K39/00 , A61K39/385 , A61K39/39 , A61P31/00 , A61P35/00 , A61P37/04
CPC分类号： A61K9/167 , A61K39/00 , A61K2039/60 , Y10S977/802 , Y10S977/803 , Y10S977/915 , Y10S977/917 , Y10S977/918 , Y10S977/92
摘要： The invention provides compositions and methods for inducing MHC class I-restricted cytotoxic T lymphocyte responses in a mammalian host by immunization with non-replicating protein antigens. The compositions of the invention comprise a particulate-protein complex capable of inducing a class I-restricted CTL response to a protein antigen in a mammal, in which the particulate protein complex comprises a particulate component having an average diameter ranging in size from about 0.5 .mu.m to about 6 .mu.m, linked to a non-replicating protein antigen derived from a tumor cell or from pathogenic organism where CTL response is likely to play an important role in conferring protective immunity in a mammal, with the proviso that the particulate component is not a prokaryotic or eukaryotic cell or a micellar multimicellar, or liposome vesicle composed of detergents or lipids. The non-replicating protein antigen is attached to the particle component through a covalent or non-covalent association to form particulate protein antigen complexes and the complexes are administered to a mammalian host in conjunction with a pharmaceutically acceptable excipient, in a CTL-stimulatory amount. The invention also provides non-replicating vaccines and methods of vaccinating a mammalian host against pathogenic diseases or tumors for CTL immunity.
摘要翻译： PCT No.PCT / US94 / 00362 Sec。 371 1995年9月15日第 102（e）1995年9月15日PCT PCT 1994年1月10日PCT公布。第WO94 / 15635号公报日期1994年7月21日本发明提供了通过用非复制蛋白抗原免疫在哺乳动物宿主中诱导MHC I类限制性细胞毒性T淋巴细胞应答的组合物和方法。本发明的组合物包含能够在哺乳动物中诱导对蛋白质抗原的I类限制性CTL应答的颗粒蛋白复合物，其中所述颗粒蛋白质复合物包含平均直径范围为约0.5μm的颗粒组分与衍生自肿瘤细胞的非复制蛋白质抗原或来自致病生物体的CTL复合蛋白抗原连接，其中CTL应答可能在哺乳动物赋予保护性免疫中起重要作用，条件是颗粒组分为不是原核或真核细胞或胶束多片剂，或由洗涤剂或脂质组成的脂质体囊泡。非复制蛋白质抗原通过共价或非共价缔合连接到颗粒组分上以形成颗粒蛋白抗原复合物，并且将复合物以CTL刺激量与药学上可接受的赋形剂联合施用于哺乳动物宿主。本发明还提供了非复制性疫苗和将哺乳动物宿主接种抗病原性疾病或肿瘤用于CTL免疫的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式